Global Neurodegenerative Diseases Market 2015-2019 is the latest addition to Sandlerresearch.org industry research reports collection. The analysts forecast the global neurodegenerative diseases market to grow at a CAGR of 4.77% over the period 2014-2019. Read this 168 Pages report on Global Neurodegenerative Diseases Market 2015-2019; the report provides 92 List of Exhibits. According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients. Some examples of neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy. Huntington’s disease and amyotrophic lateral sclerosis are rare diseases, unlike Alzheimer’s disease and Parkinson’s disease which have a high degree of prevalence. Covered in this report This report covers the present scenario and the growth prospects of the global neurodegenerative diseases market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of: • Alzheimer’s Disease • Parkinson’s Disease • Multiple Sclerosis • Epilepsy • Huntington’s Disease • Amyotrophic Lateral Sclerosis The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global neurodegenerative diseases market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.
The report, Global Neurodegenerative Diseases Market 2015-2019, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC; it also covers the global neurodegenerative diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Purchase a Report Copy at http://www.sandlerresearch.org/purchase?rname=36163 . Alternatively get Discount on the Report at http://www.sandlerresearch.org/discount?rname=36163 . Key regions
• Americas • APAC • EMEA
Key vendors
• Biogen Idec • Merck Serono • Novartis • Pfizer • Teva Pharmaceutical Industries • UCB
Other prominent vendors
• AB Science • Abbvie • Acorda Therapeutics • Actavis • Active Biotech • Adamas Pharmaceuticals • Akorn • Archer Pharmaceuticals • Astellas • Auspex Pharmaceuticals • Bayer • Boehringer Ingelheim • Covis • Desitin Arzneimittel
• Eisai • Eli Lilly • Endo International • F. Hoffmann-La Roche • FORUM Pharmaceuticals • GlaxoSmithKline • Glenmark • H. Lundbeck • Ipsen • Janssen Pharmaceuticals • Kyowa Hakko Kirin • Mitsubishi Tanabe • MorphoSys • Newron Pharmaceuticals • Omeros • Opexa • Orion • Otsuka Pharmaceutical • Oxford BioMedica • Palobiofarma • Prana Biotechnology • Raptor Pharmaceutical • Sanofi • Siena Biotech • SOM Biotech • STADA • Takeda Pharmaceutical • TauRx Pharmaceuticals • US WorldMeds • Valeant • Zinfandel Pharmaceuticals
Inquire before Buying at http://www.sandlerresearch.org/inquire-before-buying?rname=36163 . Key Market driver: High unmet medical needs Key Market challenge: Generic erosion Key Market trend: Reformulation of marketed drugs
Key questions answered in this report 1. 2. 3. 4. 5. 6. 7.
• What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors?
List of Exhibits: Exhibit 1: Market Research Methodology Exhibit 2: Global Neurodegenerative Diseases Market 2014-2019 ($ million) Exhibit 3: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease Exhibit 4: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2014 Exhibit 5: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2019 Exhibit 6: Etiology of Multiple Sclerosis Exhibit 7: Global Multiple Sclerosis Market 2014-2019 ($ million) Exhibit 8: Multiple Sclerosis Market in US 2014-2019 ($ million) Exhibit 9: Prevalence of Dementia by Geography 2013, 2030, and 2050 (million) Exhibit 10: Prevalence of Dementia by Geography 2013-2018 (millions) Exhibit 11: Types of Dementia and Associated Symptoms Exhibit 12: Types of Dementia by Prevalence 2013 Exhibit 13: Segmentation of Economic Burden of Alzheimer's Disease and Other Dementias by Geography 2013 Exhibit 14: Average Cost of Care for Americans Aged 65 and Above with Alzheimer's Disease and Other Dementias 2013 Exhibit 15: Distribution of Alzheimer's Caregivers by Age 2013 Exhibit 16: Projected Prevalence of Dependence 2010 and 2030
Exhibit 17: Global Alzheimer's Disease Market 2014-2019 ($ million) Exhibit 18: Global Epilepsy Market 2014-2019 ($ million) Exhibit 19: Epilepsy Market in US 2014-2019 ($ million) Exhibit 20: Epilepsy Market in Europe 2014-2019 ($ million) Exhibit 21: Epilepsy Market in Japan 2014-2019 ($ million) Exhibit 22: Global Parkinson's Disease Market 2014-2019 ($ million) Exhibit 23: Segmentation of Global Parkinson's Disease Market by Country 2014 Exhibit 24: Snapshot of Disease Exhibit 25: Prevalence of Huntington's Disease by Geography 2013 Exhibit 26: Huntington's Disease: Pipeline Portfolio Exhibit 27: Global Huntington's Disease Market 2014-2019 ($ million) Exhibit 28: Snapshot of Disease Exhibit 29: Amyotrophic Lateral Sclerosis: Pipeline Portfolio Exhibit 30: Global Amyotrophic Lateral Sclerosis Market 2014-2019 ($ million) Exhibit 31: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule Exhibit 32: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule 2014 Exhibit 33: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration Exhibit 34: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration 2014 Exhibit 35: Segmentation of Global Neurodegenerative Diseases Market by Geography 2014 Exhibit 36: Global Neurodegenerative Diseases Market Share Analysis 2014 Exhibit 37: Major Drugs for Neurodegenerative Diseases by Revenue 2014 ($ million) Exhibit 38: YoY Revenue of Major Drugs for Neurodegenerative Diseases 2011-2014 ($ million) Exhibit 39: Revenue Share of Major Drugs for Neurodegenerative Diseases 2011-2014
Exhibit 40: Biogen Idec: Global Revenue of Products 2011-2014 ($ million) Exhibit 41: Biogen Idec: YoY Global Revenue of Avonex 2011-2014 ($ million) Exhibit 42: Biogen Idec: Revenue of Avonex in US 2011-2014 ($ million) Exhibit 43: Biogen Idec: Revenue of Avonex in ROW 2011-2014 ($ million) Exhibit 44: Biogen Idec: YoY Global Revenue of Tysabri 2011-2014 ($ million) Exhibit 45: Biogen Idec: Revenue of Tysabri in US 2011-2014 ($ million) Exhibit 46: Biogen Idec: Revenue of Tysabri in ROW 2011-2014 ($ million) Exhibit 47: Biogen Idec: YoY Global Revenue of Fampyra 2011-2014 ($ million) Exhibit 48: Biogen Idec: Revenue of Plegridy in US and ROW 2014 ($ million) Exhibit 49: Biogen Idec: Revenue of Tecfidera in US and ROW 2013 and 2014 ($ million) Exhibit 50: Pfizer: YoY Global Revenue of Lyrica 2011-2014 ($ million) Exhibit 51: Pfizer: YoY Global Revenue of Neurontin 2011-2013 ($ million) Exhibit 52: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ million) Exhibit 53: Teva Pharmaceutical: Quarterly Revenue of Copaxone 2011-2014 ($ million) Exhibit 54: Teva Pharmaceutical: YoY Global Revenue of Azilect 2011-2014 ($ million) Exhibit 55: Teva Pharmaceutical: Quarterly Revenue of Azilect 2011-2014 ($ million) Exhibit 56: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ million) Exhibit 57: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ million) Exhibit 58: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ million) Exhibit 59: Novartis: YoY Global Revenue of Comtan/Stalevo 2011-2014 ($ million) Exhibit 60: Novartis: Revenue of Comtan/Stalevo in US and ROW 2011-2013 ($ million) Exhibit 61: Novartis: YoY Global Revenue of Exelon/Exelon Patch 2011-2014 ($ million) Exhibit 62: Novartis: Revenue of Exelon/Exelon Patch in US and ROW 2011-2013 ($ million) Exhibit 63: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ million)
Exhibit 64: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ million) Exhibit 65: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ million) Exhibit 66: Merck Serono: Revenue Share of Rebif by Region 2012-2014 Exhibit 67: UCB: YoY Global Revenue of Vimpat 2011-2014 ($ million) Exhibit 68: UCB: YoY Revenue of Vimpat in Europe 2011-2014 ($ million) Exhibit 69: UCB: YoY Revenue of Vimpat in North America 2011-2014 ($ million) Exhibit 70: UCB: YoY Global Revenue of Keppra/Keppra XR 2011-2014 ($ million) Exhibit 71: UCB: YoY Revenue of Keppra/Keppra XR in Europe 2011-2014 ($ million) Exhibit 72: UCB: YoY Revenue of Keppra/Keppra XR in North America 2011-2014 ($ million) Exhibit 73: UCB: YoY Global Revenue of Neupro 2011-2014 ($ million) Exhibit 74: UCB: YoY Revenue of Neupro in Europe 2011-2014 ($ million) Exhibit 75: UCB: YoY Revenue of Neupro in North America 2011-2014 ($ million) Exhibit 76: Biogen Idec: Business Segmentation by Revenue 2013 Exhibit 77: Biogen Idec: Geographical Segmentation by Revenue 2013 Exhibit 78: Merck Serono: Geographical Segmentation by Revenue 2013 Exhibit 79: Novartis AG: Business Segmentation Exhibit 80: Novartis AG: Revenue by Business Segmentation 2013 Exhibit 81: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million) Exhibit 82: Novartis AG: Revenue by Geographical Segmentation 2013 Exhibit 83: Pfizer: Business Segmentation by Revenue 2013 Exhibit 84: Pfizer: Business Segmentation by Revenue 2012 and 2013 Exhibit 85: Pfizer: Geographical Segmentation by Revenue 2013 Exhibit 86: Teva Pharmaceutical Industries: Business Segmentation Exhibit 87: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
Exhibit 88: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013 ($ million) Exhibit 89: Teva Pharmaceutical Industries: Sales by Geography 2013 Exhibit 90: UCB: Product Segmentation by Revenue 2013 Exhibit 91: UCB: Product Segmentation by Revenue 2012 and 2013 ($ million) Exhibit 92: UCB: Geographical Segmentation by Revenue 2013 Browse Other Reports on Pharmaceutical . Contact sales@sandlerresearch.org / Call +1 888 391 5441 for further information on “Global Neurodegenerative Diseases Market 2015-2019� report OR for any other market research and intelligence needs you may have for your business. NOTE: This Report Is NOT Free Of Charge.